April 27, 2023
Authored and Edited by Daniel F. Klodowski; Umber Aggarwal; Matthew R. Ritter; Elliot C. Cook; Aaron L. Parker
In February, 145 (22.10%) instituted claims survived review across 42 IPR and PGR Final Written Decisions, including decisions following remand from the Federal Circuit. The PTAB cancelled 511 (77.90%) instituted claims, and patent owners did not concede any instituted claims through motions to amend or disclaimer in cases reaching a final decision. For comparison, the cumulative average survival rate of instituted claims in IPR, CBM, and PGR Final Written Decisions is about 73%.
On a per-case basis, no instituted or substitute claims survived in 28 (66.67%) decisions, all instituted claims survived in 7 (16.67%) decisions, and a mixed outcome occurred in 7 (16.67%) decisions. A mixed outcome occurs where at least one instituted or substitute claim remains patentable, and at least one is cancelled, in a Final Written Decision.
In March, a relatively difficult month for patent owners, 94 (12.14%) instituted claims survived review across 51 IPR and PGR Final Written Decisions. The PTAB cancelled 660 (85.27%) instituted claims, and patent owners conceded 20 (2.58%) instituted claims.
On a per-case basis, no instituted or substitute claims survived in 39 (76.47%) decisions, all instituted claims survived in 7 (13.73%) decisions, and a mixed outcome occurred in 5 (9.80%) decisions.
Through March 31, 2023, the PTAB has cumulatively granted 595 (16.62%) proposed substitute claims in motions to amend while denying 2,986 (83.38%) proposed substitute claims in IPRs.
The overall cumulative instituted claim survival rate in IPRs, CBMs, and PGRs through March 31, 2023, broken down by technology center, is as follows:
The cumulative number of Final Written Decisions through March 31, 2023, separated by technology center, is as follows:
Additional cumulative statistics on the Board’s IPR, CBM, and PGR decisions, updated through March 31, 2023, are available here on the At the PTAB blog.
Copyright © 2023 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP.
DISCLAIMER: Although we wish to hear from you, information exchanged in this blog cannot and does not create an attorney-client relationship. Please do not post any information that you consider to be personal or confidential. If you wish for Finnegan, Henderson, Farabow, Garrett & Dunner, LLP to consider representing you, in order to establish an attorney-client relationship you must first enter a written representation agreement with Finnegan. Contact us for additional information. One of our lawyers will be happy to discuss the possibility of representation with you. Additional disclaimer information.
Lecture
Patent Protection for Software-Related Inventions in Europe and the USA Training Course
June 5, 2024
Hybrid
Webinar
Obviousness of Biologics Inventions: Strategies for Biologics Claims in the U.S., Europe, and China
May 28,2024
Webinar
Webinar
Building a Strong ADC Patent Portfolio – From Prosecution and Litigation Perspectives
May 15, 2024
Webinar
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.